A. Thako and S. Gambhir, Nanooncology: The future of cancer diagnosis and therapy, CA: A Cancer Journal for Clinicians, vol.15, issue.6, pp.395-418, 2013.
DOI : 10.1021/bc049951i

V. Weissig, T. Pettinger, and N. Murdoch, Nanopharmaceuticals (part 1): products on the market, International Journal of Nanomedicine, vol.2014, issue.9, pp.4357-4373
DOI : 10.2147/IJN.S46900
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4172146

J. Silverman and S. Deitcher, Marqibo?? (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine, Cancer Chemotherapy and Pharmacology, vol.119, issue.1, pp.555-564, 2013.
DOI : 10.1182/blood-2011-04-347872

T. Harrison and K. Lyseng-williamson, Vincristine Sulfate Liposome Injection, BioDrugs, vol.109, issue.5, pp.69-74, 2013.
DOI : 10.1182/blood-2006-08-041152

O. Deitcher, J. Glaspy, and R. Gonzalez, High-dose Vincristine Sulfate Liposome Injection (Marqibo) Is Not Associated With Clinically Meaningful Hematologic Toxicity, Clinical Lymphoma Myeloma and Leukemia, vol.14, issue.3, pp.197-202, 2014.
DOI : 10.1016/j.clml.2013.10.012

L. Kaplan, S. Deitcher, J. Silverman, and G. Morgan, Phase II Study of Vincristine Sulfate Liposome Injection (Marqibo) and Rituximab for Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma in Need of Palliative Therapy, Clinical Lymphoma Myeloma and Leukemia, vol.14, issue.1, pp.37-42, 2014.
DOI : 10.1016/j.clml.2013.09.009

M. Rodriguez, R. Pytlik, and T. Kozak, Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma, Cancer, vol.100, issue.15, pp.3475-3482, 2009.
DOI : 10.1038/bjc.1995.430

G. Batist, G. Ramakrishnan, and C. Rao, Reduced Cardiotoxicity and Preserved Antitumor Efficacy of Liposome-Encapsulated Doxorubicin and Cyclophosphamide Compared 36
DOI : 10.1200/jco.2001.19.5.1444

R. Leonard, S. Williams, and A. Tulpule, Improving the therapeutic index of anthracyline chemotherapy: Focus on liposomal doxorubicin (Myocet TM ). The Breast, pp.218-224, 2009.

L. Harris, G. Batist, and R. Belt, Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma, Cancer, vol.20, issue.1, pp.25-36, 2002.
DOI : 10.1002/cncr.10201

D. Amadori, C. Milandri, and G. Comella, A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer, European Journal of Cancer, vol.47, issue.14, pp.2091-2098, 2011.
DOI : 10.1016/j.ejca.2011.05.005

D. Barco, S. Colomer, R. Calvo, and L. , Non-pegylated liposomal doxorubicin combined with gemcitabine as first-line treatment for metastatic or locally advanced breast cancer. Final results of a phase I/II trial, Breast Cancer Research and Treatment, vol.15, issue.3, pp.351-358, 2009.
DOI : 10.7326/0003-4819-91-5-710
URL : https://hal.archives-ouvertes.fr/hal-00478274

S. Ciolli, F. Leoni, and C. Casini, The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma, British Journal of Haematology, vol.102, issue.6, pp.814-819, 2008.
DOI : 10.1200/JCO.2003.06.001

A. Levine, A. Tulpule, and B. Espina, Liposome-Encapsulated Doxorubicin in Combination With Standard Agents (cyclophosphamide, vincristine, prednisone) in Patients With Newly Diagnosed AIDS-Related Non-Hodgkin's Lymphoma: Results of Therapy and Correlates of Response, Journal of Clinical Oncology, vol.22, issue.13, pp.2662-2670, 2004.
DOI : 10.1200/JCO.2004.10.093

S. Luminari, A. Montanini, and D. Caballero, Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial, Annals of Oncology, vol.21, issue.7, pp.1492-1499, 2010.
DOI : 10.1093/annonc/mdp544

L. Rigacci, S. Mappa, and L. Nassi, Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines, Hematological Oncology, vol.16, issue.4, pp.198-203, 2007.
DOI : 10.7326/0003-4819-96-2-133

E. Stroppa, A. Bertuzzi, D. Comite, and G. , Phase I study of non-pegylated liposomal doxorubicin in combination with ifosfamide in adult patients with metastatic soft tissue sarcomas, Investigational New Drugs, vol.5, issue.6, pp.834-838, 2010.
DOI : 10.7326/0003-4819-99-6-745

Y. Barenholz, Doxil? ? The first FDA-approved nano-drug: Lessons learned, Journal of Controlled Release, vol.160, issue.2, pp.117-134, 2012.
DOI : 10.1016/j.jconrel.2012.03.020

R. Leonard, S. Williams, and A. Tulpule, Improving the therapeutic index of anthracycline chemotherapy: Focus on liposomal doxorubicin (Myocet?), The Breast, vol.18, issue.4, pp.218-224, 2009.
DOI : 10.1016/j.breast.2009.05.004

A. Secord, A. Jones, E. Hahn, and C. , Phase I/II trial of intravenous Doxil? and whole abdomen hyperthermia in patients with refractory ovarian cancer, International Journal of Hyperthermia, vol.21, issue.4, pp.333-347, 2005.
DOI : 10.1080/02656730400022260

B. El-rayes, I. D. Shields, and A. , Phase I study of liposomal doxorubicin (Doxil) and cyclophosphamide in solid tumors, Investigational New Drugs, vol.23, issue.1, pp.57-62, 2005.
DOI : 10.1023/B:DRUG.0000047106.20104.a7

M. Krauze, C. Noble, and T. Kawaguchi, Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts, Neuro-Oncology, vol.9, issue.4, pp.393-403, 2006.
DOI : 10.1215/15228517-2007-019

P. Brouckaert, N. Takahashi, V. Tiel, and S. , Tumor necrosis factor-? augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (Doxil?) correlates with altered Doxil? pharmacokinetics, International Journal of Cancer, vol.20, issue.3, pp.442-448, 2004.
DOI : 10.1002/1521-4141(2002010)32:10<2759::AID-IMMU2759>3.0.CO;2-L

P. Gill, B. Espina, and F. Muggia, Phase I/II and Pharmacokinetic Evaluation of
DOI : 10.1200/jco.1995.13.4.996

L. Daunorubicin, Fassas A, Anagnostopoulos A. The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia, Journal of clinical Oncology Leukemia & Lymphoma, vol.13, issue.466, pp.996-1003, 1995.

. Relapsed-acute-myeloid-leukemia, C. Rinaldi, and S. Palmieri, Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome ? ) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients, Liposomal Daunorubicin by the International BFM Study Group. Journal of Clinical Oncology. Annal. Hematol, vol.31, issue.88, pp.599-607, 2009.

A. Candoni, A. Michelutti, and E. Simeone, Efficacy of liposomal daunorubicin and cytarabine as reinduction chemotherapy in relapsed acute lymphoblastic leukaemia despite expression of multidrug resistance-related proteins, European Journal of Haematology, vol.18, issue.1, pp.293-299, 2006.
DOI : 10.1046/j.1365-2141.2002.03418.x

D. Russo, P. Piccaluga, and M. Michieli, Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia, Annals of Hematology, vol.81, issue.8, pp.462-466, 2002.
DOI : 10.1007/s00277-002-0509-9

G. Hempel, D. Reinhardt, and U. Creutzig, Population pharmacokinetics of liposomal daunorubicin in children, British Journal of Clinical Pharmacology, vol.92, issue.Suppl 4, pp.370-377, 2003.
DOI : 10.1046/j.1365-2125.2003.01886.x

A. Mctiernan, J. Whelan, and M. Leahy, A Phase II Nonrandomized Open-Label Study of Liposomal Daunorubicin (DaunoXome) in Advanced Soft Tissue Sarcoma, Sarcoma, vol.41080, pp.1-5, 2006.

P. Mitchell, P. Marlton, and A. Grigg, A phase II study of liposomal daunorubicin, in combination with cyclophosphamide, vincristine and prednisolone, in elderly patients with previously untreated aggressive non-Hodgkin lymphoma, Leukemia & Lymphoma, vol.87, issue.14, pp.924-931, 2008.
DOI : 10.1080/10428190600799946

H. Chang and M. Yeh, Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy, International Journal of Nanomedicine, vol.7, pp.49-60, 2012.

P. Chen, T. Ozawa, and D. Drummond, Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts, Neuro-Oncology, vol.15, issue.2, pp.189-197, 2013.
DOI : 10.1093/neuonc/nos305

A. Ko, M. Tempero, and Y. Shan, A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer, British Journal of Cancer, vol.69, issue.4, pp.920-925, 2013.
DOI : 10.1007/s00280-012-1875-1

J. Frampton and . Mifamurtide, A review of its Use in the Treatment of Osteosarcoma, Adis Drug Evaluation, vol.12, issue.3, pp.141-153, 2010.

W. Chen, Y. W. Huang, and L. , A simple but effective cancer vaccine consisting of an antigen and a cationic lipid, Cancer Immunology, Immunotherapy, vol.28, issue.Pt 9, pp.517-530, 2008.
DOI : 10.4049/jimmunol.176.3.1750

R. Poon and N. Borys, Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer, Expert Opinion on Pharmacotherapy, vol.34, issue.2, pp.333-343, 2009.
DOI : 10.1038/bjc.1977.1

M. Thomas, D. Jaffe, and M. Choti, Hepatocellular Carcinoma: Consensus Recommendations of the National Cancer Institute Clinical Trials Planning Meeting, Journal of Clinical Oncology, vol.28, issue.25, pp.3994-4005, 2010.
DOI : 10.1200/JCO.2010.28.7805

E. Miele, G. Spinelli, and E. Miele, Albumin-bound formulation of paclitaxel (Abraxane ? ABI-007) in the treatment of breast cancer, International Journal of Nanomedecine, vol.4, pp.99-105, 2009.

J. Braeckman and D. Michielsen, Efficacy and olerability of 1-and 3-month leuprorelin acetate depot formulation (Eligard/Depot-Eligard) for advanced prostate cancer in daily practice: a Belgian prospective non-interventional study, Arch. Med. Sci, vol.2014, issue.3, pp.477-483

S. Agnihotri, K. Burrell, and A. Wolf, Glioblastoma, a Brief Review of History, Molecular Genetics, Animal Models and Novel Therapeutic Strategies, Archivum Immunologiae et Therapiae Experimentalis, vol.8, issue.1, pp.25-41, 2013.
DOI : 10.1016/j.ccr.2005.07.004

H. Ishii, J. Furuse, and M. Nagase, A Phase I Study of Hepatic Arterial Infusion Chemotherapy with Zinostatin Stimalamer Alone for Hepatocellular Carcinoma, Japanese Journal of Clinical Oncology, vol.33, issue.11
DOI : 10.1093/jjco/hyg106

R. Duncan, Polymer conjugates as anticancer nanomedicines, Nature Reviews Cancer, vol.54, issue.9, pp.688-701, 2006.
DOI : 10.1038/nm1002

C. Rokx, M. Van-der-ende, and A. Verbon, Peginterferon Alfa-2a for AIDS-Associated

J. Ianotto, F. Boyer-perrard, and E. Gyan, Efficacy and safety of pegylated-interferon ?-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups, British Journal of Haematology, vol.91, issue.6, pp.783-791, 2013.
DOI : 10.1007/s12185-010-0529-5
URL : https://hal.archives-ouvertes.fr/hal-00968588

R. Go, S. Lee, and D. Shin, ECOG Phase II trial of graded-dose peginterferon ?-2b in patients with metastatic melanoma over-expressing basic fibroblast growth factor, 2602.

A. Riker, G. Rossi, and P. Masih, Combination Immunotherapy for High-Risk Resected and Metastatic Melanoma Patients. The Ochsner Journal Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo, Annual report of Bind Therapeutic PNAS, vol.14, issue.10316, pp.164-174, 2006.
DOI : 10.1200/jco.2011.29.15_suppl.8534

F. Gu, L. Zhang, and B. Teply, Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers, Proceedings of the National Academy of Sciences, vol.263, issue.5153, pp.2586-2591, 2008.
DOI : 10.1126/science.8128245

J. Hrkach, V. Hoff, D. Ali, and M. , Preclinical Development and Clinical Translation of a PSMA

S. Eliasof, L. D. Peters, and C. , Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle, Proceedings of the National Academy of Sciences, vol.118, issue.6, pp.15127-15132, 2013.
DOI : 10.1002/cncr.27647

S. Gaur, L. Chen, and Y. T. , Preclinical study of the cyclodextrin-polymer conjugate of camptothecin CRLX101 for the treatment of gastric cancer, Nanomedicine: Nanotechnology, Biology and Medicine, vol.8, issue.5, pp.721-730, 2012.
DOI : 10.1016/j.nano.2011.09.007

S. Svenson, W. M. Hwang, and J. , Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101, Journal of Controlled Release, vol.153, issue.1, pp.49-55, 2011.
DOI : 10.1016/j.jconrel.2011.03.007

G. Weiss, J. Chao, and J. Neidhart, First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies, Investigational New Drugs, vol.135, issue.Suppl 5, pp.986-1000, 2013.
DOI : 10.1007/s00432-009-0543-2

N. Desai, V. Trieu, and Z. Yao, Increased Antitumor Activity, Intratumor Paclitaxel Concentrations, and Endothelial Cell Transport of Cremophor-Free, Albumin-Bound Paclitaxel, ABI-007, Compared with Cremophor-Based Paclitaxel, where do we stand? Expert Opin, pp.1317-1324, 2006.
DOI : 10.1158/1078-0432.CCR-05-1634

G. Lyman, Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action, Expert Opinion on Biological Therapy, vol.31, issue.2, pp.1635-1646, 2005.
DOI : 10.1200/JCO.2004.09.106

F. Willis, R. Pettengell, and . Pegfilgrastim, Pegfilgrastim, Expert Opinion on Biological Therapy, vol.18, issue.13, pp.985-992, 2002.
DOI : 10.1093/annonc/mdf130

M. Morishita and R. Leonard, Pegfilgrastim; a neutrophil mediated granulocyte colony stimulating factor???expanding uses in cancer chemotherapy, Expert Opinion on Biological Therapy, vol.18, issue.7, pp.993-1001, 2008.
DOI : 10.1200/JCO.2006.08.8823

R. Goel, D. Swanlund, and J. Coad, TNF-??-based accentuation in cryoinjury--dose, delivery, and response, Molecular Cancer Therapeutics, vol.6, issue.7, pp.2039-2047, 2007.
DOI : 10.1158/1535-7163.MCT-06-0676
URL : http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.569.7448

R. Pedro, T. Thekke-adiyat, and R. Goel, Use of Tumor Necrosis Factor-alpha-coated

R. Visaria, R. Griffin, and B. Williams, Enhancement of tumor thermal therapy using gold nanoparticle-assisted tumor necrosis factor-? delivery, Molecular Cancer Therapeutics, vol.5, issue.4, pp.1014-1020, 2006.
DOI : 10.1158/1535-7163.MCT-05-0381

G. Paciotti, L. Myer, and W. , Colloidal Gold: A Novel Nanoparticle Vector for Tumor Directed Drug Delivery, Drug Delivery, vol.279, issue.3, pp.169-183, 2004.
DOI : 10.1016/S0169-409X(97)00136-1

P. Diagaradjane, A. Shetty, and J. Wang, Modulation of in Vivo Tumor Radiation Response via Gold Nanoshell-Mediated Vascular-Focused Hyperthermia: Characterizing an Integrated Antihypoxic and Localized Vascular Disrupting Targeting Strategy, Nano Letters, vol.8, issue.5, pp.1492-1500, 2008.
DOI : 10.1021/nl080496z

L. Hirsch, R. Stafford, and J. Bankson, Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance, Proceedings of the National Academy of Sciences, vol.41, issue.24, pp.13549-13544, 2003.
DOI : 10.1016/S0065-2571(00)00013-3

J. Stern, J. Stanfield, and W. Kabbani, Selective Prostate Cancer Thermal Ablation With Laser Activated Gold Nanoshells, The Journal of Urology, vol.179, issue.2, pp.748-753, 2008.
DOI : 10.1016/j.juro.2007.09.018

J. Hainfeld, F. Dilmanian, and D. Slatkin, Radiotherapy enhancement with gold nanoparticles, Journal of Pharmacy and Pharmacology, vol.169, issue.8, pp.977-985, 2008.
DOI : 10.1667/RR1080.1

J. Hainfeld, F. Dilmanian, and Z. Zhong, Gold nanoparticles enhance the radiation therapy of a murine squamous cell carcinoma. Physics in medicine and biology, pp.3045-3059, 2010.

J. Hainfeld, H. Smilowitz, O. Connor, and M. , Gold nanoparticle imaging and radiotherapy of brain tumors in mice, Nanomedicine, vol.8, issue.10, pp.1601-1609, 2013.
DOI : 10.2217/nnm.12.165

J. Hainfeld, O. Connor, M. Lin, and P. , Infrared-Transparent Gold Nanoparticles Converted by Tumors to Infrared Absorbers Cure Tumors in Mice by Photothermal Therapy, PLoS ONE, vol.21, issue.2
DOI : 10.1371/journal.pone.0088414.s016

A. Jordan, N. Waldoefner, K. Decken, R. Scholz, K. Maier-hauff et al., Active ingredient conjugates. United States patent US Intracranial thermotherapy using magnetic nanoparticles combined with external beam radiotherapy: Results of a feasibility study on patients with glioblastoma multiforme, Plosone. J. Neurooncol, vol.9, issue.81, pp.88414-84, 2006.

K. Maier-hauff, F. Ulrich, and D. Nestler, Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme, Journal of Neuro-Oncology, vol.70, issue.2, pp.317-324, 2011.
DOI : 10.1158/0008-5472.CAN-10-1022

L. Maggiorella, G. Barouch, and C. Devaux, Nanoscale radiotherapy with hafnium oxide nanoparticles, Future Oncology, vol.8, issue.9, pp.1167-1181
DOI : 10.2217/fon.12.96

E. Alphandéry, Perspectives of Breast Cancer Thermotherapies, Journal of Cancer, vol.5, issue.6, pp.472-479
DOI : 10.7150/jca.8693

E. Alphandéry, Application of Magnetosomes synthesized by magnetotactic bacteria in medicine. Frontiers in bioengineering and biotechnology, pp.1-6, 2014.

E. Alphandéry, I. Chebbi, and F. Guyot, Use of bacterial magnetosomes in the magnetic hyperthermia treatment of tumours: A review, International Journal of Hyperthermia, vol.3, issue.8, pp.801-809
DOI : 10.1038/nature04382

E. Alphandéry, L. Lijeour, and Y. Lalatonne, Different signatures between chemically and biologically synthesized nanoparticles in a magnetic sensor: A new technology for multiparametric detection, Sensors and Actuators B: Chemical, vol.147, issue.2, pp.786-790, 2010.
DOI : 10.1016/j.snb.2010.04.009

E. Alphandéry, C. Carvallo, and N. Menguy, Chains of Cobalt Doped Magnetosomes Extracted from AMB-1 Magnetotactic Bacteria for Application in Alternative Magnetic Field Cancer Therapy, The Journal of Physical Chemistry C, vol.115, issue.24, pp.11920-11924, 2011.
DOI : 10.1021/jp201274g

E. Alphandéry, S. Faure, and L. Raison, Heat Production by Bacterial Magnetosomes Exposed to an Oscillating Magnetic Field, The Journal of Physical Chemistry C, vol.115, issue.1, pp.18-22, 2011.
DOI : 10.1021/jp104580t

E. Alphandéry, M. Amor, and F. Guyot, The effect of iron-chelating agents on Magnetospirillum magneticum strain AMB-1: stimulated growth and magnetosome production and improved magnetosome heating properties, Applied Microbiology and Biotechnology, vol.91, issue.3, pp.663-670, 2012.
DOI : 10.1385/ABAB:91-93:1-9:155

E. Alphandéry, F. Guyot, and I. Chebbi, Preparation of chains of Magnetosomes from Magnetospirillum magneticum strain AMB-1 magnetotactic bacteria, p.46

S. Sadeghi, O. Olevsky, and S. Hurvitz, Profiling and targeting HER-2-positive breast cancer using trastuzumab emtansine, Pharmacogenomics and Personalized Medicine, vol.7, pp.329-338, 2014.

S. M. Ansell, H. Tang, and P. J. Kurtin, Denileukin Diftitox in Combination with Retuximab for Previously Untreated Follecular B-cell Non-Hodgkin's Lymphoma. Leukemia, pp.1046-1052, 2012.

G. Chen, S. Zhang, and X. He, Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives, OncoTargets and Therapy, vol.7, pp.1901-1909, 2014.
DOI : 10.2147/OTT.S50483
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4211860

J. Li, J. Pan, and X. Zhu, Recombinant adenovirus-p53 (Gendicine) sensitizes a pancreatic carcinoma cell line to radiation, Chinese Journal of Cancer Research, vol.25, pp.715-721, 2013.

M. Mathur and G. Vyas, Role of nanoparticles for production of smart herbal drug-An overview, Indian Journal of Natural Products and Resources, vol.4, pp.329-338, 2013.

V. Weissig, T. Pettinger, and N. Murdock, Nanopharmaceuticals (part 1): products on the market, International Journal of Nanomedicine, vol.2014, issue.9, pp.4357-4373
DOI : 10.2147/IJN.S46900

M. Yallapu, M. Jaggi, and S. Chauhan, Curcumin nanoformulations: a future nanomedicine for cancer, Drug Discovery Today, vol.17, issue.1-2, pp.71-80, 2012.
DOI : 10.1016/j.drudis.2011.09.009
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3259195

O. Koo, I. Rubinstein, and H. Onyuksel, Camptothecin in sterically stabilized phospholipid micelles: A novel nanomedicine, Nanomedicine: Nanotechnology, Biology and Medicine, vol.1, issue.1, pp.77-84, 2005.
DOI : 10.1016/j.nano.2004.11.002

M. Ucisik, S. Kupcu, and B. Schuster, Characterization of CurcuEmulsomes: nanoformulation for enhanced solubility and delivery of curcumin, Journal of Nanobiotechnology, vol.11, issue.1, p.37, 2013.
DOI : 10.1002/pca.1129

E. Markovsky, H. Baabur-cohen, and A. Eldar-boock, Administration, distribution, metabolism and elimination of polymer therapeutics, Journal of Controlled Release, vol.161, issue.2, pp.446-460, 2012.
DOI : 10.1016/j.jconrel.2011.12.021

D. Fourmy, J. Carrey, and V. Gigoux, Targeted nanoscale magnetic hyperthermia: challenges and potentials of peptide-based targeting, Nanomedicine, vol.10, issue.6, pp.893-896, 2015.
DOI : 10.2217/nnm.14.236

F. Kievit and M. Zhang, Surface Engineering of Iron Oxide Nanoparticles for Targeted Cancer Therapy, Accounts of Chemical Research, vol.44, issue.10, pp.853-862, 2011.
DOI : 10.1021/ar2000277

M. Wieder, D. Hone, and M. Cook, Intracellular photodynamic therapy with photosensitizer-nanoparticle conjugates: cancer therapy using a ?Trojan horse?, Photochem. Photobiol. Sci., vol.1, issue.8
DOI : 10.1039/b108586g

S. Onoue, S. Yamada, and H. Chan, Nanodrugs: pharmacokinetics and safety, International Journal of Nanomedicine, vol.9, pp.1025-1037, 2014.
DOI : 10.2147/IJN.S38378
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3934594

A. Thako and S. Gambhir, Nanooncology: The future of cancer diagnosis and therapy, CA: A Cancer Journal for Clinicians, vol.15, issue.6, pp.395-418, 2013.
DOI : 10.1021/bc049951i

F. Ehmann, K. Sakai-kato, and R. Duncan, Next-generation nanomedicines and nanosimilars: EU regulators? initiatives relating to the development and evaluation of nanomedicines, Nanomedicine, vol.8, issue.5, pp.849-856, 2013.
DOI : 10.2217/nnm.13.68

N. Desai, Challenges in Development of Nanoparticle-Based Therapeutics. The AAPS Journal, pp.282-295, 2012.

A. Jordan, R. Scholz, and K. Maier6hauff, The effect of thermotherapy using magnetic nanoparticles on rat malignant glioma, Journal of Neuro-Oncology, vol.89, issue.1, pp.7-14, 2006.
DOI : 10.1111/j.1349-7006.1998.tb00586.x

S. Handy, E. Ivkov, R. Ellis-busby, and D. , Foreman A, inventors; Triton Biosystem Inc., assignee. Thermotherapy via targeted delivery of nanoscale magnetic particles. United States patent US, 2003.

A. Jordan, N. Waldoefner, K. Decken, R. Scholz, and . Nanoparticle, Active ingredient conjugates. United States patent US, 2006.

N. Waldoefner and K. Stief, Magnetic transducers. United States patent US 20110052609, 2010.

B. Thiesen, A. Jordan, A. Nanotechnologies, and . Assignee, Implantable products comprising nanoparticles. United States patent US 20110223255, 2009.

E. Alphandéry, S. Faure, I. Chebbi, and . Nanobacterie, Treatment of cancer or tumors induced by the release of heat generated by various chains of Magnetosomes extracted from magnetotactic bacteria and submitted to an alternative magnetic field, 2010.

E. Alphandéry, I. Chebbi, and C. Upmc, Use of at least one iron chelate introduced in the bacterial growth medium to stimulate the growth of these bacteria

J. Hainfeld and . Inventor, Nanoprobes Inc., assignee; Methods and composition for increasing infrared absorptivity of a target, 2008.

W. Liu and J. Hainfeld, inventor; Nanoprobes Inc, assignee; 5 nm Nickel-NTA-Gold Nanoparticles, 2012.

. Nanobiotix, Activatable particles, preparations and uses, 2005.

L. Lévy and A. Boussaha, Panak EA, inventors; Nanobiotix assignee, Nanoparticles comprising an intracellular targeting element and preparation and use thereof, 2006.

L. Levy, A. Pottier, A. Rouet, J. Marill, C. Devaux et al., inventors; Nanobiotix, assignee, Inorganic nanoparticles, preparation and uses thereof, 20085.

L. Lévy, A. Pottier, and L. Puoi, Maggiorella L, inventors; Nanobiotix, assignee, Metallic nanoparticles, preparation and uses thereof, 200910-06.

A. Pottier and L. Lévy, Meyre ME, inventors ; Nanobiotix assignee, Nanoparticles comprising metallic and hafnium oxide materials, preparation and uses thereof, p.17, 2012.

S. Krishnan, P. Diagaradjane, J. Schwartz, and J. Wang, inventors; University of Texas and Nanospectra, assignee. Treatment of disease or disorders using nanoparticles for focused hyperthermia to increase therapy efficacy, 201316-01.

S. Krishanan, P. Diagaradjane, and G. Goodrich, The University of Texas and Nanospectra Inc, assignee. Enhancement of radiation therapy by targeted high-z nanoparticles, 20105-04.

J. Hainfeld and D. Slatkin, NanoProbes Inc; Methods of enhancing radiation effects with metal nanoparticles, 200923-07.

X. Mei, J. Qinggwei, and Y. W. , inventors; Celsion Corp, assignee, Thermosensitive liposomes containing therapeutic agents, 201118-08.

. For, K. Hong, and D. Drummond, Kirpotin D, inventors; Merrimack Pharmaceuticals Inc, assignee. Liposome useful for drug delivery, 201316.

J. Cheng and M. Davis, Khin KT, inventors; Cerulean Pharma Inc, assignee; Cyclodextrinbased polymers for therapeutic delivery, 201325-07.

M. For-example-figueiredo, E. Peeke, and D. Dewitt, inventors; Bind Therapeutics Inc., assignee. Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same, 201426-06.

N. Jadhav, T. Powar, S. Shinde, and S. Nadaf, Herbal nanoparticles: A patent review Asian journal of Pharmaceutics, pp.58-69, 2014.

R. Bosetti and L. Vereeck, Future of nanomedicine: obstacles and remedies, Nanomedicine, vol.6, issue.4, pp.747-755, 2011.
DOI : 10.2217/nnm.11.55

R. Edison, Magforce, accelerating on the US highway, 2014.

R. Edison, Nanobiotix, Good things come in small packages

. Edison and . Research, BioAlliance Pharma Awaiting Onxeo, 2014.

M. Transparency and . Research, Nanomedicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013.

S. Libutti, G. Paciotti, and A. Byrnes, Phase I and Pharmacokinetic Studies of CYT- 6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine, Clin. Cancer Research, pp.16-6139, 2010.

J. Schwartz, R. Price, and K. Gill-sharp, Selective Nanoparticle-Directed Ablation of the Canine Prostate, Lasers in Surgery and Medicine, pp.213-220, 2011.

M. Johannsen, U. Gneveckow, and B. Thiesen, Thermotherapy of Prostate Cancer Using Magnetic Nanoparticles: Feasibility, Imaging, and Three-Dimensional Temperature Distribution, European Urology, vol.52, issue.6, pp.1653-1662, 2007.
DOI : 10.1016/j.eururo.2006.11.023

E. Vasievich, W. Chen, and L. Huang, Enantiospecific adjuvant activity of cationic lipid DOTAP in cancer vaccine, Cancer Immun. Immunother, pp.629-638, 2011.

M. Puhlmann and P. Soriano, Direct evidence for rapid and selective induction of tumor neovascular permeability by tumor necrosis factor and a novel derivative, colloidal gold bound tumor necrosis factor, 82294&CIK=1274792 152. Notice of Marqibo, pp.2474-2480, 2007.

R. Bardhan, W. Chen, and M. Bartels, Tracking of Multimodal Therapeutic Nanocomplexes Targeting Breast Cancer in Vivo, NANO Letters CRLX101 (formerly IT-101)-A Novel Nanopharmaceutical of Campthotecin in Clinical Development, Current Bioactive Compounds, vol.10, issue.7, pp.4920-4928, 2011.

J. Hainfeld, H. Smilowitz, O. Connor, and M. , Gold nanoparticle imaging and radiotherapy of brain tumors in mice Delivery of Liposomal Doxorubicin (Doxil) in a Breast Cancer Tumor Model: Investigation of Potential Enhancement by Pulsed-High Intensity Focused Ultrasound Exposure Academic radiology, Future Medicine, vol.8, issue.134, pp.1601-1609, 2006.

P. Rose, J. Blessing, and S. Lele, Evaluation of pegylated doxorubicin (Doxil) as secondline chemotherapy of squamous cell carcinoma of the cervix: A phase II study of the Gynecologic Oncology Group. Genecologie Oncology, pp.210-213, 2006.

G. Kaspers, M. Zimmermann, and D. Reinhardt, Improved Outcome in Pediatric Relapsed Acute Myeloid Leukemia: Results of a Randomized Trial on Liposomal Daunorubicin by the International BFM Study Group, Journal of Clinical Oncology, vol.31, issue.5, pp.599-607, 2013.
DOI : 10.1200/JCO.2012.43.7384

F. Willis and P. R. Pegfilgrastim, Pegfilgrastim, Expert Opinion on Biological Therapy, vol.18, issue.13, pp.985-992, 2002.
DOI : 10.1093/annonc/mdf130